SrasV1, 2020, Analysis, bibRecord, 000483

Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.

Identifieur interne : 000483 ( 2020/Analysis ); précédent : 000482; suivant : 000484

Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.

Auteurs : Tony Y. Zhang [République populaire de Chine] ; Boyu Zhong [République populaire de Chine]

Source :

Medicine in drug discovery [ 2590-0986 ] ; 2020.

RBID : pubmed:32292908

Abstract

This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus SARS-CoV-2, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the surge in demand.

DOI: 10.1016/j.medidd.2020.100036
PubMed: 32292908

Affiliations:

République populaire de Chine

Links to Exploration step

pubmed:32292908

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.</title>
<author><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name>
<affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32292908</idno>
<idno type="pmid">32292908</idno>
<idno type="doi">10.1016/j.medidd.2020.100036</idno>
<idno type="wicri:Area/PubMed/Corpus">000125</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000125</idno>
<idno type="wicri:Area/PubMed/Curation">000125</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000125</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000391</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000391</idno>
<idno type="wicri:Area/Ncbi/Merge">003A66</idno>
<idno type="wicri:Area/Ncbi/Curation">003A66</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003A66</idno>
<idno type="wicri:Area/Main/Merge">000483</idno>
<idno type="wicri:Area/Main/Curation">000483</idno>
<idno type="wicri:Area/Main/Exploration">000483</idno>
<idno type="wicri:Area/2020/Extraction">000483</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.</title>
<author><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name>
<affiliation wicri:level="1"><nlm:affiliation>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Tyligand Bioscience Ltd. 3728 Jinke Road, Building 1, Zhangjiang Hitech Park, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Medicine in drug discovery</title>
<idno type="eISSN">2590-0986</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><i>This paper provides an overview of the current global market and manufacturing landscape for hydroxychloroquine (HCQ). The capacity and capabilities of global producers to meet the potential demand for treating patients inflicted with COVID-19 by the novel corona virus</i>
 SARS-CoV-2<i>, should HCQ's efficacy be established by more definitive clinical trials, is also assessed. Given the large existing manufacturing base and abundance of raw materials for HCQ, the supply challenge can be met with considerable efforts and international cooperation. Preemptive and coordinated emergency efforts among global governments, regulatory agencies, chemical and pharmaceutical industries are imperative for meeting the surge in demand</i>
.</div>
</front>
</TEI>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
</list>
<tree><country name="République populaire de Chine"><noRegion><name sortKey="Zhang, Tony Y" sort="Zhang, Tony Y" uniqKey="Zhang T" first="Tony Y" last="Zhang">Tony Y. Zhang</name>
</noRegion>
<name sortKey="Zhong, Boyu" sort="Zhong, Boyu" uniqKey="Zhong B" first="Boyu" last="Zhong">Boyu Zhong</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000483 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000483 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:32292908
   |texte=   Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i   -Sk "pubmed:32292908" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.

Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.